What is NeuroScience?
Established in 2000, NeuroScience operates as a privately-owned entity focused on the production of professional-grade dietary supplements. The company's core innovation lies in its proprietary blends of amino acids, specifically engineered to serve as precursors for neurotransmitters, critical molecules within the nervous system. This specialized focus targets a niche within the health and wellness sector, emphasizing the biochemical pathways of neurological function.
How much funding has NeuroScience raised?
NeuroScience has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in NeuroScience
PPP
Public-Private Partnership
What's next for NeuroScience?
The substantial large-scale late-stage funding indicates NeuroScience is poised for significant expansion and market penetration. This strategic capital infusion is likely to fuel advancements in product development, enhance manufacturing capabilities, and broaden distribution channels. The company's focus on neurotransmitter precursors suggests potential for further research into neurological health applications, positioning it for sustained growth in the competitive dietary supplement industry.
See full NeuroScience company page
